Treatment of non small cell lung cancer with alectinib

EP4770646A1Pending Publication Date: 2026-07-08F HOFFMANN LA ROCHE & CO AG
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
F HOFFMANN LA ROCHE & CO AG
Filing Date
2024-08-28
Publication Date
2026-07-08

AI Technical Summary

Technical Problem

Current treatments for early-stage anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) are inadequate in preventing disease recurrence, particularly in patients with resected stage lb ALK-positive NSCLC with tumors greater than or equal to 4cm to stage Illa ALK-positive NSCLC.

Method used

Administering a therapeutically effective amount of alectinib, or its pharmaceutically acceptable salt, as adjuvant therapy to patients with resected stage lb ALK-positive NSCLC with tumors greater than or equal to 4cm to stage Illa ALK-positive NSCLC, thereby preventing recurrence.

Benefits of technology

Alectinib adjuvant therapy significantly reduces the risk of disease recurrence in patients with early-stage ALK-positive NSCLC, demonstrating a 76% reduction in disease recurrence or new primary NSCLC compared to platinum-based chemotherapy, as shown in clinical trial data.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000005_0001
    Figure IMGF000005_0001
  • Figure IMGF000037_0001
    Figure IMGF000037_0001
  • Figure IMGF000038_0001
    Figure IMGF000038_0001
Patent Text Reader

Abstract

The present invention relates to a method of treating anaplastic lymphoma kinase (ALK)- positive non-small cell lung cancer (NSCLC), comprising administering to a subject in need of such treatment a therapeutically effective amount of alectinib, or a pharmaceutically acceptable salt thereof, wherein the subject has resected stage Ib ALK-positive NSCLC with a tumour greater or equal to 4cm to stage IIIa ALK-positive NSCLC.
Need to check novelty before this filing date? Find Prior Art